Evidence map›Paper›PMID 36960864›Full record

ArticleOncology reports2023

Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells.

Deborah S Souza, Carla Macheroni, Carolina M Vicente, Renan P Cavalheiro, Vanessa L Campo, Catarina S Porto

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Deborah S SouzaLaboratory of Experimental Endocrinology, Department of Pharmacology, Paulista School of Medicine (EPM), Federal University of São Paulo (UNIFESP), São Paulo, SP 04039‑032, Brazil.
Carla MacheroniLaboratory of Experimental Endocrinology, Department of Pharmacology, Paulista School of Medicine (EPM), Federal University of São Paulo (UNIFESP), São Paulo, SP 04039‑032, Brazil.
Carolina M VicenteLaboratory of Experimental Endocrinology, Department of Pharmacology, Paulista School of Medicine (EPM), Federal University of São Paulo (UNIFESP), São Paulo, SP 04039‑032, Brazil.
Renan P CavalheiroDepartment of Biochemistry, Paulista School of Medicine (EPM), Federal University of São Paulo (UNIFESP), São Paulo, SP 04039‑032, Brazil.
Vanessa L CampoBarão de Mauá University Center (CBM), Ribeirão Preto, SP 14090‑180, Brazil.
Catarina S PortoLaboratory of Experimental Endocrinology, Department of Pharmacology, Paulista School of Medicine (EPM), Federal University of São Paulo (UNIFESP), São Paulo, SP 04039‑032, Brazil.
Universidade Federal de São Paulo · BRCentro Universitário Barão de Mauá · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to investigate the role of estrogen receptor (ER)α and ERβ, and galectin‑3 (GAL‑3) in migration and invasion of androgen‑independent DU‑145 prostate cancer cells, and to examine the regulation of the expression of GAL‑3 by the activation of these receptors. Wound healing and cell invasion assays were performed using the control (basal level of cellular function) and treated DU‑145 cells. At 24 h of treatment, 17β‑estradiol (E2), the ERα‑selective agonist, 4,4',4"‑(4‑propyl‑(1H)‑pyrazole‑1,3,5‑triyl)trisphenol (PPT), or the ERβ‑selective agonist, 2,3‑bis(4‑hydroxyphenyl)‑propionitrile (diarylprepionitrile; DPN), increased the migration and invasion of the DU‑145 cells. Pre‑treatment with the ERα‑ and ERβ‑selective antagonists blocked these effects, indicating that ERα and ERβ are upstream receptors regulating these processes. Western blot analysis and immunofluorescence staining for the detection of the GAL‑3 were performed using the control and treated DU‑145 cells. Treatment of the DU‑145 cells with E2, PPT or DPN for 24 h increased the expression of the GAL‑3 compared to the control. Furthermore, a specific inhibitor of GAL‑3 (VA03) inhibited the migration and invasion of DU‑145 cells, indicating the involvement of the complex ERα/GAL‑3 and ERβ/GAL‑3 in the regulation of these processes. On the whole, the present study demonstrates that the activation of both ERs increases the expression and signaling of GAL‑3, and promotes the migration and invasion of DU‑145 cells. The findings of the present study provide novel insight into the signatures and molecular mechanisms of ERα and ERβ in DU‑145 cells.

Indexed as

Prostatic NeoplasmsReceptors, EstrogenAndrogensEstradiolEstrogen Receptor alphaEstrogen Receptor betaGalectin 3HumansMaleAndrogensEstradiolEstrogen Receptor alphaEstrogen Receptor betaGalectin 3Receptors, Estrogenestrogen receptorgalectin‑3migration and invasionprostate cancer cells

Identifiers

PMID36960864
PMCPMC10086566
OpenAlexW4327953245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.